MOLECULAR DOCKING STUDY ON 1-(3-(4-BENZYLPIPERAZIN-1-YL)PROPYL)-3,7-DIMETHYL-1H-PURINE-2,6(3H,7H)-DIONE AS AN ACETYLCHOLINESTERASE INHIBITOR
Abstract
Acetylcholinesterase (AChE) is a good target in the design of new drugs for the treatment of Alzheimer’s disease. The currently known drugs -donepezil, galantamine and rivastignime- act as moderate AChE inhibitors. In the present study, we docked a newly synthesized arylpiperazine derivative 1-(3-(4-benzylpiperazin-1-yl)propyl)-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione (LA1) into rhAChE and identified its binding mode. The docking pose of the studied LA1 molecule depends of the protonated state of the nitrogen atom of the piperazine moiety where in the best scored poses, the xanthine moiety of LA1 is bound into the catalytic active site (CAS) of AChE, while the arylpiperazine fragment is placed into the peripheral binding site (PAS). The Ellman’s test confirmed the compound binding. LA1 has good permeability through the GIT and BBB assessed by PAMPA. LA1 is a prospective lead for AChE inhibition.
References
Andonova, L., Zheleva-Dimitrova, D., Georgieva, M., Zlatkov, A. (2014).Synthesis and antioxidant activity of some 1-aryl/ aralkyl piperazine derivatives with xanthine moiety at N4. Biotechnology & Biotechnological Equipment, 28:6, 1165-1171.
Atanasova M, Yordanov N, Dimitrov I, Berkov S, Doytchinova I (2015a) Molecular docking study on galantamine derivatives as cholinesterase inhibitors. MolInf 34: 394-403. PMID: 27490385
Atanasova M, Stavrakov G, Philipova I, Zheleva D, Yordanov N (2015b) Galantamine derivatives with indole moiety: docking, design, synthesis and acetylcholinesterase activity. Bioorg Med Chem 23: 5382-5389. PMID: 26260334
Barnard, E.A. (1974) Neuromuscular transmission - enzymatic destruction of acetylcholine. In: Hubbard J.I., editor.The Peripheral Nervous System.Plenum; New York: pp. 201–224.
Cheung J, Rudolph MJ, Burshteun F, Cassidy MS, Gary EN, et al. (2012) Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 55: 10282-10286. PMID: 23035744
Čolović,M.B., Krstić,D.Z., Lazarević-Pašti,T.D.,Bondžić,A.M., Vasić,V.M. (2013). Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. Curr Neuropharmacol, 11(3), 315–335.
Dvir, H., Silman, I., Harel, M., Rosenberry, T.L., Sussman, J.L. (2010). Acetylcholinesterase: From 3D Structure to Function. Chem Biol Interact, 187(1-3): 10–22.
Ellman, G.L., Courtney, K.D., Andres, V., Feather-Stone, R.M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity.Biochem Pharmacol., 7:88-95.
Kitz, R. J., Braswell, L. M., Ginsburg, S. (1970). On the question: is acetylcholinesterase an allosteric protein?.Mol. Pharmacol.,6(2):108-21
Meng, X., Zhang, H., Mezei, M., Cui, M. (2011).Molecular Docking: A powerful approach for structure-based drug discovery.Curr Comput Aided Drug Des., 7(2): 146–157.
Modh, R.P., Kumar, S.P., Jasrai, Y.T., Chikhalia, K.H. (2013). Design, synthesis, biological evaluation, and molecular modeling of coumarin-piperazine derivatives as acetylcholinesterase inhibitors. Arch Pharm (Weinheim), 346(11):793-804
Mohamed, T., Osman, W., Tin, G., Rao, P.P. (2013).Selective inhibition of human acetylcholinesterase by xanthine derivatives: in vitro inhibition and molecular modeling investigations. Bioorg Med Chem Lett, 23(15):4336-41
Molecular Operating Environment (MOE), 2013.08; Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2018.
Molinspiration Cheminformatics, 2017, retrieved from www.molinspiration.com
Özkay, Ü.D., Can, Ö.D., Sağlık, B.N., Çevik, U.A., Levent, S., Özkay,Y., Ilgın, S., Atlı, Ö.(2016). Design, synthesis, and AChE inhibitory activity of new benzothiazole-piperazines.Bioorg Med Chem Lett, 26(22):5387-5394
Pohanka, M., Dobes, P. (2013). Caffeine Inhibits Acetylcholinesterase, But Not Butyrylcholinesterase. Int. J. Mol. Sci., 14(5), 9873-9882.
Rose, A.S., Bradley, A.R., Valasatava, Y., Duarte, J.M., Prlić, A., Rose, P.W. (2016) Web-based molecular graphics for large complexes. ACM Proceedings of the 21st International Conference on Web3D Technology (Web3D '16): 185-186.
Stavrakov G, Philipova I, Zheleva D, Atanasova M, Konstantinov S (2016) Docking-based design of galantamine derivatives with dual-site binding to acetylcholinesterase. MolInf 35: 278-285. PMID: 27492242
Stavrakov G, Philipova I, Zheleva-Dimitrova D, Valkova I, Konstantinov S (2017).Docking-based design and synthesis of galantamine-camphane hybrids as inhibitors of acetylcholinesterase.ChemBiol Drug Des 90: 709-718. PMID: 28374576
Tata, A.M., Velluto, L., D'Angelo, C., Reale, M. (2014).Cholinergic system dysfunction and neurodegenerative diseases: cause or effect?. CNS NeurolDisord Drug Targets, 13(7):1294-303.
Yurttaş, L., Kaplancıklı, Z.A., Özkay, Y.(2013). Design, synthesis and evaluation of new thiazole-piperazines as acetylcholinesterase inhibitors.J Enzyme Inhib Med Chem, 28(5):1040-7.
Copyright information
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (Creative Commons Attribution License 3.0 - CC BY 3.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
info@iseic.cz, www.iseic.cz, ojs.journals.cz
